Page 17 - U11248 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from U11248. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In U11248 Today - Breaking & Trending Today

T-DXd: 'Remarkable' Survival Gains in Advanced Breast Cancer

The antibody-drug conjugate trastuzumab deruxtecan continues to show impressive progression-free and overall survival gains in previously treated unresectable and/or metastatic HER2+ breast cancer. ....

United States , New Haven , Sara Hurvitz , Los Angeles , Ian Krop , Rachel Abelman , University Of California , University Hospital , Yale Cancer Center , Jonsson Comprehensive Cancer Center , San Antonio Breast Cancer Symposium , Drug Aministration , Elche General University Hospital , Later Lines , Past Results , Massachusetts General Hospital , Medscape Medical News , Lung Disease , Adverse Event , Third Line , Second Line , Metastatic Breast Carcinoma , Breast Cancer , Alignant Breast Neoplasm , Biologic Therapy , Antineoplastic Drug ,

New Oral SERD Elacestrant -- for Which Breast Cancer Patients?

New data from the pivotal trial elacestrant in patients with ER+/HER2- metastatic breast cancer show subgroups that get the greatest progression-free survival benefit. ....

New York , United States , France General , San Antonio , Shipra Gandhi , Fabrice Andr , Roswell Park Comprehensive Cancer Center , Ut Health San Antonio Cancer Center , Breast Cancer Program , Drug Administration , Gustave Roussy Cancer Center , Virginia Kaklamani , San Antonio Cancer Center , San Antonio Breast Cancer Symposium , Metastatic Breast Carcinoma , Breast Cancer , Alignant Breast Neoplasm , Antineoplastic Drug , Nti Cancer Agents , Alignant Neoplasia , Endocrine Therapy , Adverse Effects , Side Effects , Estrogen Therapy , Sinus Bradycardia ,

MCL: Ibrutinib Could Become the 'New Standard'

New results with ibrutinib could put an end to autologous hematopoietic stem cell transplantation for treating younger patients with mantle cell lymphoma (MCL). ....

United States , Narendranath Epperla , Martin Dreyling , Lilly Loxo , American Society Of Hematology , Ludwig Maximilian University , Ohio State University , Drug Administration , American Society , Transplantation Stem Cell , Ransplantation Hematopoietic Stem Cell , Hematopoietic Stem Cell Transplantation , Stem Cell Transplantation , Stem Cell Therapy , Herapy Stem Cell , Transplantation Cellular , Cellular Transplantation , Biologic Therapy , Malignant Lymphoma , Mantle Cell Lymphoma , Tyrosine Kinase Inhibitor ,

High Response Rates With T-DXd in Early HER2-Low Breast Cancer

"The study provides a rich platform for additional translational research to evaluate more sensitive methods of HER2 detection." ....

United States , San Antonio , Jasona Mouabbi , Aditya Bardia , Daiichi Sankyo , Eli Lilly , Fresenius Kabi , University Of Texas Md Anderson Cancer Center , Hospital Cancer Center , Translational Research In Oncology , Napo Pharmaceuticals , Cardinal Health , Radius Health , Immunomedics Gilead Sciences , Massachusetts General Hospital Cancer Center , Antonio Breast Cancer , Cancer Center , Gilead Sciences , Breast Cancer , Alignant Breast Neoplasm , Biologic Therapy , Alignant Neoplasia , Antineoplastic Drug , Nti Cancer Agents , Translational Research , Ranslative Research ,

High Response Rates With Talquetamab in Advanced Myeloma

The investigational, bispecific T-cell engager homes in on GPRC5D, a novel target unique to malignant plasma cells. It is awaiting approval from the Food and Drug Administration. ....

New York , United States , Stephanie Lee , Astrazeneca Incyte , Mount Sinai School Of Medicine , Drug Administration , International Staging System , Fred Hutchinson Cancer Center , American Society Of Hematology , Ajai Chari , Mount Sinai School , American Society , New England Journal , Medscape Medical News , Multiple Myeloma , Plasma Cell Myeloma , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents , Drug Development , Chimeric Antigen Receptort Cell Therapy , Chimeric Antigen Receptors , Himeric Immunoreceptors , Himerict Cell Receptors , Rtificialt Cell Receptors , Ar T ,